CoChat
Sign Up
Cited by 44

The DOI matches its Crossref record.

Lipid profiles of prostate cancer cells

Sorvina, Alexandra, Bader, Christie A., Caporale, Chiara, Carter, Elizabeth A., Johnson, Ian R.D., Parkinson-Lawrence, Emma J., Simpson, Peter V., Wright, Phillip J., Stagni, Stefano, Lay, Peter A., Massi, Massimiliano, Brooks, Douglas A., Plush, Sally E.·2018·Oncotarget
DOI 10.18632/oncotarget.26222PMC PMC6238979
Open this paper in CoChat — free account

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.18632/oncotarget.26222

Cites

Statistics

Figures

Figure 1 Quantitative LC-ESI-MS/MS data analysis of the relative abundances of lipids in prostate cell lines (a) Comparison of average concentrations [nmol mg-1 protein] of (CE) cholesteryl esters, (SM) sphingomyelin, (FC) free cholesterol, (PE) phosphatidylethanolamine, (PC) phosphatidylcholine and (GM) gangliosides in prostate cell lines for six parallel samples with their standard error. One-way ANOVA and Tukey's multiple comparison tests showed significant differences among the means for the samples (depicted by different letters on the bars, p < 0.05). (b) The PCA scores plot comparing non-malignant PNT1a (black circles) and prostate cancer cell lines DU145 (green squares), 22RV1 (blue triangles) and LNCaP (red diamonds), using identified lipid species. (c) Loadings plot of PCA for PC-1 (equal to 78%). (d) Comparison of average concentrations [nmol mg-1 protein] of lipids that allowed the differentiation of non-malignant PNT1a and prostate cancer cell lines, DU145, 22RV1 and LNCaP (p < 0.05). Data presented as mean ± SEM of six independent biological replicates for each of the four prostate cell lines.
Figure 1 Quantitative LC-ESI-MS/MS data analysis of the relative abundances of lipids in prostate cell lines (a) Comparison of average concentrations [nmol mg-1 protein] of (CE) cholesteryl esters, (SM) sphingomyelin, (FC) free cholesterol, (PE) phosphatidylethanolamine, (PC) phosphatidylcholine and (GM) gangliosides in prostate cell lines for six parallel samples with their standard error. One-way ANOVA and Tukey's multiple comparison tests showed significant differences among the means for the samples (depicted by different letters on the bars, p < 0.05). (b) The PCA scores plot comparing non-malignant PNT1a (black circles) and prostate cancer cell lines DU145 (green squares), 22RV1 (blue triangles) and LNCaP (red diamonds), using identified lipid species. (c) Loadings plot of PCA for PC-1 (equal to 78%). (d) Comparison of average concentrations [nmol mg-1 protein] of lipids that allowed the differentiation of non-malignant PNT1a and prostate cancer cell lines, DU145, 22RV1 and LNCaP (p < 0.05). Data presented as mean ± SEM of six independent biological replicates for each of the four prostate cell lines.CC BY · PubMed Central
Figure 2 FTIR spectroscopy on prostate cancer cells (a-d) Optical and (a/-d/) FTIR images collected by integrating the area under the νs(CH2) band (2862–2847 cm-1) and generated from (a, a/) PNT1a and prostate cancer cell lines, (b, b/) DU145, (c, c/) 22RV1 and (d, d/) LNCaP. (e) Average FTIR spectra from PNT1a (black) and prostate cancer cell lines, DU145 (green), 22RV1 (blue) and LNCaP (red), acquired over the 3600–900 cm-1 spectral region, where (A) C–H and (B) C=O bands were located. (f) Averaged spectra of the C–H stretching region (3000–2800 cm-1) with band assignment. (g) Second-derivative spectra of the C–H stretching region shown in f. (h) Second-derivative spectra of the C=O stretching region.
Figure 2 FTIR spectroscopy on prostate cancer cells (a-d) Optical and (a/-d/) FTIR images collected by integrating the area under the νs(CH2) band (2862–2847 cm-1) and generated from (a, a/) PNT1a and prostate cancer cell lines, (b, b/) DU145, (c, c/) 22RV1 and (d, d/) LNCaP. (e) Average FTIR spectra from PNT1a (black) and prostate cancer cell lines, DU145 (green), 22RV1 (blue) and LNCaP (red), acquired over the 3600–900 cm-1 spectral region, where (A) C–H and (B) C=O bands were located. (f) Averaged spectra of the C–H stretching region (3000–2800 cm-1) with band assignment. (g) Second-derivative spectra of the C–H stretching region shown in f. (h) Second-derivative spectra of the C=O stretching region.CC BY · PubMed Central
Figure 3 Distribution of lipids in prostate cancer cells (a-l) Micrographs of cross-sections through prostate cells that show the intracellular location of neutral and polar lipids. Cholesterol was depicted by staining cells with Filipin III (a-d). Neutral lipids such as triglycerides and cholesteryl esters were detected by staining cells with BODIPY® 493/503 (e-h). ReZolve-L1™ (i-l) was used for staining polar lipids. Representative images from non-malignant PNT1a (a, e, i) and prostate cancer DU145 (b, f, j), 22RV1 (c, g, k) and LNCaP (d, h, l) cell lines. Prostate cells were fixed with 4% PFA (a-h) or imaged live (i-l). Scale bars, 20 μm.
Figure 3 Distribution of lipids in prostate cancer cells (a-l) Micrographs of cross-sections through prostate cells that show the intracellular location of neutral and polar lipids. Cholesterol was depicted by staining cells with Filipin III (a-d). Neutral lipids such as triglycerides and cholesteryl esters were detected by staining cells with BODIPY® 493/503 (e-h). ReZolve-L1™ (i-l) was used for staining polar lipids. Representative images from non-malignant PNT1a (a, e, i) and prostate cancer DU145 (b, f, j), 22RV1 (c, g, k) and LNCaP (d, h, l) cell lines. Prostate cells were fixed with 4% PFA (a-h) or imaged live (i-l). Scale bars, 20 μm.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

No references could be resolved yet.

Research works printed but not linked: 45

  1. Chiaradonna, 2011, Oncogenic K-Ras decouples glucose and glutamine metabolism to support cancer cell growth, Mol Syst Biol, 7, 523, 10.1038/msb.2011.56 · DOI · Paper page
  2. Guillaumond, 2016, Lipid metabolic reprogramming in cancer cells, Oncogenesis, 5, e189, 10.1038/oncsis.2015.49 · DOI
  3. Ghesani, 2010, Dominant uptake of fatty acid over glucose by prostate cells: a potential new diagnostic and therapeutic approach, Anticancer Res, 30, 369
  4. Pauza, 2005, FAS expression inversely correlates with PTEN level in prostate cancer and a PI 3-kinase inhibitor synergizes with FAS siRNA to induce apoptosis, Oncogene, 24, 5389, 10.1038/sj.onc.1208555 · DOI
  5. Iiizumi, 2008, Fatty acid synthase gene is up-regulated by hypoxia via activation of Akt and sterol regulatory element binding protein-1, Cancer Res, 68, 1003, 10.1158/0008-5472.CAN-07-2489 · DOI
  6. Ng, 2018, An aberrant SREBP-dependent lipogenic program promotes metastatic prostate cancer, Nat Genet, 50, 206, 10.1038/s41588-017-0027-2 · DOI
  7. Mills, 2014, Androgen-regulated metabolism and biosynthesis in prostate cancer, Endocr Relat Cancer, 21, T57, 10.1530/ERC-13-0515 · DOI
  8. Bigler, 2012, Identification of plasma lipid biomarkers for prostate cancer by lipidomics and bioinformatics, PLoS One, 7, e48889, 10.1371/journal.pone.0048889 · DOI
  9. Cheng, 2014, Cholesteryl ester accumulation induced by PTEN loss and PI3K/AKT activation underlies human prostate cancer aggressiveness, Cell Metab, 19, 393, 10.1016/j.cmet.2014.01.019 · DOI
  10. Xu, 2016, Integration of lipidomics and transcriptomics unravels aberrant lipid metabolism and defines cholesteryl oleate as potential biomarker of prostate cancer, Sci Rep, 6, 20984, 10.1038/srep20984 · DOI
  11. Daly, 2017, A distinct plasma lipid signature associated with poor prognosis in castration-resistant prostate cancer, Int J Cancer, 141, 2112, 10.1002/ijc.30903 · DOI
  12. Clarke, 2008, FTIR-based spectroscopic analysis in the identification of clinically aggressive prostate cancer, Br J Cancer, 99, 1859, 10.1038/sj.bjc.6604753 · DOI
  13. Gardner, 2009, Investigating FTIR based histopathology for the diagnosis of prostate cancer, J Biophotonics, 2, 104, 10.1002/jbio.200810062 · DOI
  14. Goormaghtigh, 2014, Lipid quantification method using FTIR spectroscopy applied on cancer cell extracts, Biochim Biophys Acta, 1841, 1200, 10.1016/j.bbalip.2013.10.010 · DOI
  15. Plush, 2016, Unprecedented staining of polar lipids by a luminescent rhenium complex revealed by FTIR microspectroscopy in adipocytes, Mol Biosyst, 12, 2064, 10.1039/C6MB00242K · DOI
  16. Wilson, 1991, Heterogeneity in plasminogen activator (PA) levels in human prostate cancer cell lines: increased PA activity correlates with biologically aggressive behavior, Prostate, 18, 201, 10.1002/pros.2990180303 · DOI
  17. Dong, 2007, A novel synthetic compound that interrupts androgen receptor signaling in human prostate cancer cells, Mol Cancer Ther, 6, 2057, 10.1158/1535-7163.MCT-06-0735 · DOI
  18. Auner, 2014, Emerging technology: applications of Raman spectroscopy for prostate cancer, Cancer Metastasis Rev, 33, 673, 10.1007/s10555-013-9489-6 · DOI
  19. Goldys, 2014, Modulation of the organelle specificity in Re(i) tetrazolato complexes leads to labeling of lipid droplets, RSC Advances, 4, 16345, 10.1039/C4RA00050A · DOI
  20. Massi, 2016, A Molecular Probe for the Detection of Polar Lipids in Live Cells, PLoS One, 11, e0161557, 10.1371/journal.pone.0161557 · DOI
  21. Ting, 2013, Dysregulation of cholesterol homeostasis in human prostate cancer through loss of ABCA1, Cancer Res, 73, 1211, 10.1158/0008-5472.CAN-12-3128 · DOI
  22. Steck, 2012, Activation mobilizes the cholesterol in the late endosomes-lysosomes of Niemann Pick type C cells, PLoS One, 7, e30051, 10.1371/journal.pone.0030051 · DOI
  23. Wüstner, 2012, Analysis of cholesterol trafficking with fluorescent probes, Methods Cell Biol, 108, 367, 10.1016/B978-0-12-386487-1.00017-1 · DOI · Paper page
  24. Llorente, 2015, The ether lipid precursor hexadecylglycerol stimulates the release and changes the composition of exosomes derived from PC-3 cells, J Biol Chem, 290, 4225, 10.1074/jbc.M114.593962 · DOI
  25. Llorente, 2017, Molecular lipid species in urinary exosomes as potential prostate cancer biomarkers, Eur J Cancer, 70, 122, 10.1016/j.ejca.2016.10.011 · DOI
  26. Vance, 1999, Diminished expression of phosphatidylethanolamine N-methyltransferase 2 during hepatocarcinogenesis, Biochem J, 337, 23, 10.1042/bj3370023 · DOI
  27. Li, 2015, In situ characterizing membrane lipid phenotype of breast cancer cells using mass spectrometry profiling, Sci Rep, 5, 11298, 10.1038/srep11298 · DOI
  28. Sysi-Aho, 2011, Novel theranostic opportunities offered by characterization of altered membrane lipid metabolism in breast cancer progression, Cancer Res, 71, 3236, 10.1158/0008-5472.CAN-10-3894 · DOI
  29. Chen, 2014, Tissue imaging and serum lipidomic profiling for screening potential biomarkers of thyroid tumors by matrix-assisted laser desorption/ionization-Fourier transform ion cyclotron resonance mass spectrometry, Anal Bioanal Chem, 406, 4357, 10.1007/s00216-014-7846-0 · DOI
  30. Mi, 2015, Phosphatidylethanolamine-binding protein 4 promotes lung cancer cells proliferation and invasion via PI3K/Akt/mTOR axis, J Thorac Dis, 7, 1806
  31. Waelkens, 2010, De novo lipogenesis protects cancer cells from free radicals and chemotherapeutics by promoting membrane lipid saturation, Cancer Res, 70, 8117, 10.1158/0008-5472.CAN-09-3871 · DOI
  32. Koide, 2010, Characterization of the Raf kinase inhibitory protein (RKIP) binding pocket: NMR-based screening identifies small-molecule ligands, PLoS One, 5, e10479, 10.1371/journal.pone.0010479 · DOI
  33. Kolch, 2011, Raf kinase inhibitor protein RKIP enhances signaling by glycogen synthase kinase-3β, Cancer Res, 71, 1334, 10.1158/0008-5472.CAN-10-3102 · DOI
  34. Keller, 2015, Raf kinase inhibitor protein (RKIP) deficiency decreases latency of tumorigenesis and increases metastasis in a murine genetic model of prostate cancer, Prostate, 75, 292, 10.1002/pros.22915 · DOI
  35. Hannun, 2004, Biologically active sphingolipids in cancer pathogenesis and treatment, Nat Rev Cancer, 4, 604, 10.1038/nrc1411 · DOI
  36. Sandvig, 2013, Molecular lipidomics of exosomes released by PC-3 prostate cancer cells, Biochim Biophys Acta, 1831, 1302, 10.1016/j.bbalip.2013.04.011 · DOI
  37. Mur, 2016, The metabolomic detection of lung cancer biomarkers in sputum, Lung Cancer, 94, 88, 10.1016/j.lungcan.2016.02.006 · DOI
  38. Andreeff, 2012, Ganglioside GD2 identifies breast cancer stem cells and promotes tumorigenesis, J Clin Invest, 122, 2066, 10.1172/JCI59735 · DOI
  39. Sewer, 2008, Multiple roles for sphingolipids in steroid hormone biosynthesis, Subcell Biochem, 49, 387, 10.1007/978-1-4020-8831-5_15 · DOI
  40. Swinnen, 2016, Androgen control of lipid metabolism in prostate cancer: novel insights and future applications, Endocr Relat Cancer, 23, R219, 10.1530/ERC-15-0556 · DOI
  41. Maitland, 1997, Androgens are not a direct requirement for the proliferation of human prostatic epithelium, Int J Cancer, 73, 910, 10.1002/(SICI)1097-0215(19971210)73:6<910::AID-IJC25>3.0.CO;2-6 · DOI
  42. Sloane Stanley, 1957, A simple method for the isolation and purification of total lipides from animal tissues, J Biol Chem, 226, 497, 10.1016/S0021-9258(18)64849-5 · DOI · Paper page
  43. Schmitz, 2006, High throughput quantification of cholesterol and cholesteryl ester by electrospray ionization tandem mass spectrometry (ESI-MS/MS), Biochim Biophys Acta, 1761, 121, 10.1016/j.bbalip.2005.12.007 · DOI
  44. Chen, 2010, Silicon nitride as a versatile growth substrate for microspectroscopic imaging and mapping of individual cells, Mol Biosyst, 6, 1316, 10.1039/c001499k · DOI
  45. Martin, 2007, IR microspectroscopy: potential applications in cervical cancer screening, Cancer Lett, 246, 1, 10.1016/j.canlet.2006.03.019 · DOI

Cited by

Sorted by citations

See all 44

Metadata

Authors
Sorvina, A., Bader, C. A., Caporale, C., Carter, E. A., Johnson, I. R. D., Parkinson-Lawrence, E. J., Simpson, P. V., Wright, P. J., Stagni, S., Lay, P. A., Massi, M., Brooks, D. A., & Plush, S. E.
Affiliations
  • Mechanisms in Cell Biology and Disease Research Group, School of Pharmacy and Medical Sciences, Sansom Institute for Health Research, University of South Australia, Adelaide, Australia
  • School of Molecular and Life Science - Curtin Institute for Functional Molecules and Interfaces, Curtin University, Bentley, Australia
  • Sydney Analytical and School of Chemistry, The University of Sydney, Sydney, Australia
  • Department of Industrial Chemistry “Toso Montanari”, University of Bologna, Bologna, Bologna, Italy
Venue
Oncotarget
Publisher
Impact Journals, LLC
Published
2018-10-30
Volume
9
Issue
85
Pages
35541-35552
ISSN
1949-2553
DOI
10.18632/oncotarget.26222
PMC
PMC6238979
Cited by
44
References
0
Language
en

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Lipid profiles of prostate cancer cells. https://app.cochat.ai/papers/10.18632/oncotarget.26222
The paper
Sorvina, A., Bader, C. A., Caporale, C., Carter, E. A., Johnson, I. R. D., Parkinson-Lawrence, E. J., Simpson, P. V., Wright, P. J., Stagni, S., Lay, P. A., Massi, M., Brooks, D. A., & Plush, S. E. (2018). Lipid profiles of prostate cancer cells. Oncotarget. https://doi.org/10.18632/oncotarget.26222